Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of subcutaneous amivantamab plus lazertinib or platinum-based chemotherapy in EGFR-mutated advanced NSCLC
2025-520730-28-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, open-label trial of amivantamab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival (PFS). Planned start Nov 2025; status: authorised.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-520730-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520730-28-00.